Ultimovacs AB
559144-3162ActivePioneering off-the-shelf TCR-NK cell therapies to cure solid cancers.
Publicly Listed Biotechnology Companyultimovacs.com
Yleiskatsaus
- 0
- Työntekijät
- 5–10milj SEK
- Liikevaihto
- 2018
- Perustettu
Avainpäättäjät
Namir Hassan
CEO
Kuvaus
Zelluna is a biotechnology company dedicated to pioneering novel cell therapies for the treatment of cancer patients. Their core mission is to eliminate solid cancers by developing T cell receptor (TCR) guided natural killer (NK) cell therapies, known as TCR-NK. This proprietary platform aims to ove...
Tunnisteet
B2BB2CPharmaceuticals
ZELLUNA IMMUNOTHERAPY AS